Poolbeg Pharma Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	4.2	4.89	5.26	3.38	3.06	2.71
Research & Development	1.87	1.53	1.38	1.68	2.2	0.55
Other Operating Expenses	-0.03	-0.09	-0.07	-0.37	-0.28	-0.15
Operating Expenses	6.05	6.33	6.57	4.69	4.99	3.11
Operating Income	-6.05	-6.33	-6.57	-4.69	-4.99	-3.11
Interest & Investment Income	0.22	0.25	0.43	0.53	0.21	-
EBT Excluding Unusual Items	-5.82	-6.08	-6.14	-4.15	-4.78	-3.11
Gain (Loss) on Sale of Assets	-0.01	-0.01	-0.26	-	-	-
Asset Writedown	-0.03	-0.03	-	-0.35	-	-
Other Unusual Items	0.34	0.34	0.46	-	-	-
Pretax Income	-5.52	-5.77	-5.94	-4.51	-4.78	-3.11
Income Tax Expense	-0.06	-0.08	-0.15	-0.57	-0.09	-
Net Income	-5.46	-5.7	-5.79	-3.93	-4.69	-3.11
Net Income to Common	-5.46	-5.7	-5.79	-3.93	-4.69	-3.11
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	701	603	500	500	500	317
Shares Outstanding (Diluted)	701	603	500	500	500	317
Shares Change	39.33%	20.53%	-	-	57.62%	-
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EBITDA	-5.98	-6.27	-6.46	-4.66	-4.96	-3.09
D&A For EBITDA	0.07	0.06	0.11	0.03	0.03	0.02
EBIT	-6.05	-6.33	-6.57	-4.69	-4.99	-3.11